|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.17/--
|
企業價值
712.27M
|
資產負債 |
每股賬面淨值
5.01
|
現金流量 |
現金流量率
--
|
損益表 |
收益
155.84M
|
每股收益
0.76
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States. |